ReviewThe Lancet. Infectious diseases2013
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.
Review in The Lancet. Infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 862 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
862 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Resistance profile and influence factors of carbapenem-resistant Klebsiella pneumoniae (CRKP) causing infections in China: a systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2025Pooled it
- Pooled it
- Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: A systematic review of 128 articles across 30 countries.PLoS medicine · 2023Pooled it
- Review and analysis of the overlapping threats of carbapenem and polymyxin resistant E. coli and Klebsiella in Africa.Antimicrobial resistance and infection control · 2023Pooled it
- Transmission of carbapenemase-producing Enterobacter in Ontario, Canada: a retrospective genomic analysis.Emerging microbes & infections · 2026Article
- Dissemination ofEmerging microbes & infections · 2026Article
- High exposure, rapid turnover: strain-level dynamics ofMicrobiology spectrum · 2026Article
- Frequency of Klebsiella spp. and Antimicrobial Resistance Patterns in Clinically Healthy Captive Night Monkeys (Aotus nancymaae) in the Peruvian Amazon.Journal of medical primatology · 2026Article
- Performance evaluation of antimicrobial susceptibility testing methods for ceftazidime-avibactam and imipenem-relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Molecular characterization and co-occurrence of ESBL, carbapenemase and mcr-1 genes in Klebsiella pneumoniae from poultry production systems in Pakistan.Molecular biology reports · 2026Article
- A fitness advantage from the pLVPK plasmid fuels the global spread of a carbapenem-resistant hypervirulent Klebsiella pneumoniae high-risk clone: ST11-KL64.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Screening Strategies to Control Antibiotic-Resistant Bacteria: An Agent-Based Model.Antibiotics (Basel, Switzerland) · 2026Article
- Convergence of Plasmid-Mediated tmexCD-toprJ With Critical Resistance Genes Fuels Spread of Multidrug Resistant Bacteria.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A posttranslational modification of fimbriae drives pathogenicity inProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Emergence of Ceftazidime-Avibactam-Induced KPC Variants (KPC-25/127) in Intracranial Infection and Implications for Clinical Management.MicrobiologyOpen · 2026Article
- Clinical outcomes and therapeutic approaches in pediatric infections caused by metallo-β-lactamase-producing organisms: a five-year experience in a tertiary care hospital.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Bacterial pathogens and antimicrobial resistance patterns in infections associated with stillbirths and under-five deaths in Ethiopia: a post-mortem surveillance study.BMC infectious diseases · 2026Article
- Standardized numbering and alignment of the KPC family of β-lactamases.Antimicrobial agents and chemotherapy · 2026Article
- Escalating burden and mortality of carbapenem-resistant Klebsiella pneumoniae species complex infections in Bangladeshi infants.npj antimicrobials and resistance · 2026Article
- Characterization of KPC-160, a novel Ω-loop-deleted KPC variant on a dual-copy plasmid that confers cefiderocol resistance.Antimicrobial agents and chemotherapy · 2026Article
802 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Funding
Abstract
Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile β-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.